Albany Molecular Research, Inc. (AMRI)

[mlkrborn]

Albany Molecular beats by $0.01, beats on revs (AMRI) 4.36 : Reports Q2 (Jun) loss of $0.02 per share, $0.01 better than the Capital IQ Consensus Estimate of ($0.03); revenues rose 8.9% year/year to $53.9 mln vs the $52.4 mln consensus. "In the third quarter, we expect contract revenue to range from $43 million to $47 million, an increase of up to 10% versus 2010. For the full year 2011, we continue to expect contract revenue to range from $179 million to $187 million, an increase of up to 15% versus 2010."